The popular narrative says ADHD can be a startup advantage. A new 28-year study found that benefit was concentrated among a ...

The FDA approved a new ADHD drug in July. The coverage says it's a non-stimulant, first-in-class, stimulant-like. I read all ...

Once believed to be a condition that children outgrow, attention deficit hyperactivity disorder (ADHD) is now recognized as a ...

The U.S. Food and Drug Administration has approved Simtriyo (centanafadine) for the treatment of ...

Phone alarms are what get teaching assistant Layla through her day. She has four alarms to wake up, one to get dressed, another to pack her work bag, and so on. "There's a million different ones.

Simtriyo was just approved by the U.S. Food and Drug Administration to treat attention-deficit/hyperactivity disorder (ADHD) in children, teens, and adults. The ADHD ...

For decades, ADHD was viewed as a childhood condition that mostly affected boys. Researchers now know ADHD manifests differently in girls, but many still go undiagnosed until adulthood.

The FDA has approved Simtriyo (centanafadine), a first-in-class NDSRI and CNS stimulant, for adult and pediatric ADHD aged 6 years and older.

If you ever listen to the same song over and over on repeat, if you’re overwhelmed by laundry and dishes to be washed, if you’re struggling in your relationship, overstimulated by your kids running ...

Now that science understands that girls get ADHD as well as boys, studies show symptoms differ between genders.